What RoslinCT does

RoslinCT is a UK-headquartered, transatlantic contract development and manufacturing organization (CDMO) specializing in advanced cell and gene therapies, including autologous and allogeneic cell therapies, gene-edited therapies, and induced pluripotent stem cell (iPSC)-based therapies. Founded in 2006 as a spin-out from the University of Edinburgh's Roslin Institute — the birthplace of Dolly the Sheep — the company provides end-to-end services spanning process and analytical development, cGMP cell banking, manufacturing science and technology transfer, clinical and commercial manufacturing, quality and regulatory compliance, supply chain and logistics, and a training academy. Its scientific credentials include being one of the first organizations globally to produce clinical-grade human iPSCs and manufacturing exa-cel (Casgevy), the world's first FDA-approved CRISPR-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, in collaboration with Vertex Pharmaceuticals.

The company operates 22 purpose-built cGMP cell therapy processing suites across two sites — Edinburgh, Scotland (headquarters, 40,000 sq ft, 8 suites) and Hopkinton, Massachusetts (64,000 sq ft, 14 suites, acquired via the 2022 merger with Lykan Bioscience). It is a private, PE-backed entity majority-owned by GHO Capital Partners with WindRose Health Investors retaining a board-level position. RoslinCT employs approximately 300 staff (with the website claiming 500+) and has produced more than 500 cGMP batches supporting 20+ cell types.

Revenue is generated through fee-for-service CDMO contracts — project-based, clinical-stage, and commercial-scale manufacturing agreements with biotech and pharma therapy developers. The commercial-manufacturing portfolio includes exa-cel (for Vertex) and Omisirge (for Ayrmid Pharma/Gamida Cell), with recent additions including a Phase III manufacturing partnership with BOOST Pharma for BT-101. GTM is enterprise field sales with dedicated business development teams covering UK/Europe and the US, leveraging direct outreach, industry conferences, and inbound inquiries. Pricing is not publicly disclosed and is project/quote-based.

Name

RoslinCT

Legal name

RoslinCT is a trading name of Roslin Cell Therapies Limited and RoslinCT US Holdings LLC

Website

https://roslinct.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Short description

RoslinCT is a transatlantic cell and gene therapy CDMO headquartered in Edinburgh, operating 22 cGMP suites in the UK and US to provide process development, manufacturing, and commercial supply for autologous, allogeneic, gene-edited, and iPSC-based therapies for biotech and pharma clients.

Ownership category

akta.pro rank

Product category

Cell Therapy Contract Manufacturing (CDMO)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Cell therapy CDMO
• CGMP manufacturing
• IPSC development
• Gene therapy services
• Contract development manufacturing

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services: RoslinCT generates revenue by providing fee-for-service CDMO solutions including process development, analytical development, cGMP clinical and commercial manufacturing, and technology transfer services for cell and gene therapy companies. Revenue is earned through project-based contracts, service agreements, and long-term manufacturing partnerships with therapy developers. The company supports both autologous and allogeneic cell therapies and iPSC-based programs across various phases from preclinical through commercial launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

RoslinCT is a global Contract Development and Manufacturing Organization (CDMO) specializing in advanced cell and gene therapies. The company provides end-to-end cGMP manufacturing services including process and analytical development, cell banking, iPSC development, gene editing, clinical and commercial manufacturing, and supply chain/logistics, supporting both autologous and allogeneic therapies from early development through commercialization.

Product overview

RoslinCT is an advanced cell and gene therapy Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of services from early development through commercialization. The core platform consists of cGMP iPSC Development (pioneering pluripotent stem cell capabilities), Process & Analytical Development, cGMP Cell Banking, Manufacturing Science & Technology, Clinical & Commercial Manufacturing, Quality & Regulatory Compliance, and Supply Chain & Logistics, all supported by a Training Academy. RoslinCT has manufactured commercial products including exa-cel (the world's first CRISPR-edited cell therapy for Vertex Pharmaceuticals) and Omisirge (FDA-approved cell therapy for Ayrmid/Gamida Cell). The company supports both autologous and allogeneic cell therapy manufacturing through 22 purpose-built cGMP suites across Edinburgh, Scotland and Hopkinton, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

• cGMP iPSC Development

Quantifiable outcome

• 500+ cGMP batches produced for various indications
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered major and flagship.

• BOOST PharmamajorStrategic or Co-development Partner · 7 January 2026RoslinCT entered a strategic manufacturing partnership with BOOST Pharma to support Phase III development of BT-101, an allogeneic mesenchymal stem cell therapy for Osteogenesis Imperfecta (brittle bone disease) in infants. BOOST Pharma transferred its manufacturing process to RoslinCT's Edinburgh facilities. The partnership includes end-to-end CDMO support for starting materials and clinical drug product, with a long-term view toward commercial manufacturing. BOOST Pharma was founded on science from Karolinska Institutet and is supported by Industrifonden, Sound Bioventures, and Karolinska Development.
• Ayrmid Pharma Ltd. / Gamida CellmajorStrategic or Co-development Partner · 11 March 2025RoslinCT and Ayrmid Pharma Ltd. entered into a strategic partnership for the technology transfer and commercial manufacturing of Omisirge (omidubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy for hematologic malignancies. Manufacturing is being performed at RoslinCT's Hopkinton, MA facility. The partnership was later expanded in December 2025 to include manufacturing for Omisirge's second FDA-approved indication in severe aplastic anemia (SAA). Ayrmid acquired Gamida Cell, the original developer of Omisirge.
• Vertex PharmaceuticalsflagshipStrategic or Co-development PartnerIn collaboration with Vertex Pharmaceuticals, RoslinCT developed, from early process development through commercialization, the first CRISPR-edited cell therapy product (exa-cel / exagamglogene autotemcel / Casgevy) for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. This represents the world's first CRISPR gene editing therapy to receive regulatory approvals (UK, US, EU, Bahrain, Saudi Arabia, Canada) and is priced at approximately $2.2 million per patient.

Scale indicators8 records

Recent moves8 records

Expansion highlights4 records

Emerging players

• Cellares: Emerging cell therapy manufacturing automation company offering Cell Shuttle platform for automated, scalable cell therapy manufacturing. Comparable as a cell therapy manufacturing services provider, though focused on automation versus traditional CDMO service model.
• Kincell Bio: Cell therapy development and manufacturing CDMO focused on autologous and allogeneic therapies. Comparable as a specialized cell therapy CDMO with similar customer base; Jessica Carmen, RoslinCT's CCO, previously served as VP of Business Development at Kincell Bio.

Direct peers

• Aldevron (Danaher): Specialized CDMO for plasmid DNA, mRNA, proteins, and gene editing enzymes serving cell and gene therapy developers. Acquired by Danaher for $9.6B in 2021; comparable as a specialized CDMO serving cell/gene therapy market (Michael Chambers co-founded Aldevron and sits on RoslinCT SAB).
• Oxford Biomedica: UK-based cell and gene therapy CDMO specializing in viral vector and cell therapy manufacturing. Comparable as a transatlantic-focused advanced therapy CDMO serving similar biopharma customers with similar cell/gene therapy manufacturing capabilities.
• ReciBioPharm: Cell and gene therapy CDMO offering viral vector and nucleic acid manufacturing services. Directly comparable as a specialized advanced therapy CDMO serving similar biotech customers; Dean Morris, RoslinCT's US COO, joined from ReciBioPharm.
• Cellistic: iPSC-based cell therapy CDMO focused on allogeneic iPSC-derived cell therapy manufacturing. Closely comparable as a specialist cell therapy CDMO with iPSC capabilities serving similar therapy developer customers.
• 3P Biopharmaceuticals: Spanish-based biologics and cell therapy CDMO with process development and GMP manufacturing capabilities. Comparable as a specialized biologics/cell therapy CDMO serving biopharma customers; Alexandra Brownfield, RoslinCT's Head of BD, previously served as Head of BD at 3P Biopharmaceuticals.

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO leader with significant cell and gene therapy manufacturing capabilities including the acquired PharmaCell business. Directly comparable as a cell therapy CDMO serving similar biopharma clients but at much larger scale and broader service portfolio.
• Catalent (Novo Holdings): Major global CDMO with cell therapy manufacturing capabilities as part of broader biologics and drug delivery portfolio. Comparable as a CDMO serving biopharma, but with substantially larger scale and integrated services.
• Charles River Laboratories: Large CRO/CDMO with cell therapy manufacturing services (CDMO division). Comparable as a contract manufacturer serving biopharma, but with much broader portfolio including preclinical research, biologics, and discovery services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles36 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RoslinCT